XML 28 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jul. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Jul. 09, 2019
Collaboration And Other Agreements [Line Items]          
Revenues   $ 13,682 $ 9,662    
Deferred revenue, current   9,506   $ 10,700  
Deferred revenue, net of current portion   8,100   9,153  
I-Mab | I-Mab Biopharma Collaboration and License Agreement          
Collaboration And Other Agreements [Line Items]          
Non-refundable upfront payment $ 15,000        
Potential development and regulatory milestone payments under agreement         $ 135,000
Estimated variable consideration $ 1,000        
Revenues   1,100      
Deferred revenue   12,400   13,500  
Deferred revenue, current   4,300   4,400  
Deferred revenue, net of current portion   $ 8,100   $ 9,100  
I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum          
Collaboration And Other Agreements [Line Items]          
Potential proceeds from royalties (percent) 20.00%